Effectiveness of UV-C Technology for Environmental Decontamination of Clostridioides difficile in Hospital Settings: A Pre-Post Analysis - Top-Institutions - MDSpire

Effectiveness of UV-C Technology for Environmental Decontamination of Clostridioides difficile in Hospital Settings: A Pre-Post Analysis

  • By

  • Nofar Fourman

  • Esther Houri-Levi

  • Eyal Meltzer

  • Bella Mechnik

  • Nani Pinas-Zade

  • Leonid Maizels

  • Yehudit Eden-Friedman

  • Shir Raibman-Spector

  • Gili Regev-Yochay

  • Mayan Gilboa

  • January 12, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Infectious Diseases
    • Hospital Epidemiology
    • Infection Control

  • #2

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Hospital Epidemiology
    • Clinical Research

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Infectious Diseases
    • Hospital Epidemiology
    • Clinical Trials

  • #4

    Sheba Medical Center
    Sheba Medical Center

    Ramat Gan, Israel

    Key Differentiators

    • Infectious Diseases
    • Hospital Epidemiology
    • Environmental Microbiology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Hospital Epidemiology
    • Clinical Research

Original Source(s)

Effectiveness of UV-C Technology for Environmental Decontamination of Clostridioides difficile in Hospital Settings: A Pre-Post Analysis

  • by Nofar Fourman, Esther Houri-Levi, Eyal Meltzer, Bella Mechnik, Nani Pinas-Zade, Leonid Maizels, Yehudit Eden-Friedman, Shir Raibman-Spector, Gili Regev-Yochay, Mayan Gilboa

  • January 12, 2026

Related Content

Reply to Olle et al.

Correspondence to “Escape Velocity—The Launch of Microbiome Therapies”

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.